KROS
Keros Therapeutics, Inc. Healthcare - Biotechnology Investor Relations →
Keros Therapeutics, Inc. (KROS) closed at $10.96 as of 2026-03-20, trading 69.1% below its 200-week moving average of $35.46. This places KROS in the extreme value zone. The stock is currently moving closer to the line, down from -69.0% last week. With a 14-week RSI of 13, KROS is in oversold territory.
A big spike in selling this week — 2.6x the usual volume, and the price dropped. Sometimes this kind of heavy selling marks the end of a decline. The idea is that the last reluctant holders have finally sold, leaving fewer sellers left to push the price lower.
Over the past 262 weeks of data, KROS has crossed below its 200-week moving average 12 times. On average, these episodes lasted 14 weeks. The average one-year return after crossing below was -21.7%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $334 million, KROS is a small-cap stock. The company generates a free cash flow yield of 19.8%, which is notably high. Return on equity stands at 19.9%, a solid level. The stock trades at 0.7x book value.
The company has been aggressively buying back shares, reducing its share count by 29.0% over the past three years. KROS passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow. This stock also meets the Yartseva multibagger criteria as a small-cap with strong free cash flow yield and reasonable book value.
Over the past 5.1 years, a hypothetical investment of $100 in KROS would have grown to $19, compared to $176 for the S&P 500. KROS has returned -28.1% annualized vs 11.7% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: KROS vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After KROS Crosses Below the Line?
Across 12 historical episodes, buying KROS when it crossed below its 200-week moving average produced an average return of -14.6% after 12 months (median -17.0%), compared to +11.8% for the S&P 500 over the same periods. 42% of those episodes were profitable after one year. After 24 months, the average return was -18.5% vs +30.6% for the index.
Each line shows $100 invested at the moment KROS crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
KROS has crossed below its 200-week MA 12 times with an average 1-year return of +-21.7% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| May 2021 | Jun 2021 | 4 | 6.6% | -10.0% | -77.6% |
| Jun 2021 | Nov 2021 | 19 | 36.1% | -36.4% | -75.6% |
| Jan 2022 | Feb 2022 | 3 | 12.8% | +9.2% | -76.3% |
| May 2022 | Oct 2022 | 25 | 43.1% | -7.3% | -77.0% |
| Nov 2022 | Nov 2022 | 2 | 1.2% | -35.8% | -76.2% |
| Dec 2022 | Dec 2022 | 1 | 0.0% | -18.2% | -76.5% |
| Mar 2023 | May 2023 | 10 | 17.3% | +59.2% | -75.2% |
| Jun 2023 | Jan 2024 | 30 | 39.5% | +10.9% | -75.0% |
| May 2024 | Jun 2024 | 1 | 2.0% | -69.8% | -76.6% |
| Jun 2024 | Jul 2024 | 4 | 11.8% | -71.0% | -76.4% |
| Aug 2024 | Sep 2024 | 4 | 5.5% | -69.7% | -75.8% |
| Dec 2024 | Ongoing | 67+ | 77.0% | Ongoing | -41.8% |
| Average | 14 | — | +-21.7% | — |
Frequently Asked Questions
Is KROS below its 200-week moving average?
Yes. As of 2026-03-20, Keros Therapeutics, Inc. (KROS) is trading 69.1% below its 200-week moving average of $35.46. The current price is $10.96.
What is KROS's 200-week moving average price?
Keros Therapeutics, Inc.'s 200-week moving average is $35.46 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when KROS drops below its 200-week moving average?
KROS has crossed below its 200-week moving average 12 times in our data. The average one-year return after these crossings was -21.7%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 14 weeks on average.
Is KROS a good value right now?
Here's what our data says about KROS as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 13 (oversold). Free cash flow yield is 19.8%. Return on equity is 19.9%. Price-to-book is 0.7x. This is not a buy or sell recommendation — always do your own research.
How does KROS compare to the S&P 500?
Over the past 5.1 years, $100 invested in KROS would have grown to $19, compared to $176 for the S&P 500. That's -28.1% annualized vs 11.7% for the index. KROS has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20